A Role for VEGF as a Negative Regulator of Pericyte Function and Vessel Maturation

Department of Surgery, School of Medicine, Moore's UCSD Cancer Center, USA.
Nature (Impact Factor: 42.35). 12/2008; 456(7223):809-13. DOI: 10.1038/nature07424
Source: PubMed

ABSTRACT Angiogenesis does not only depend on endothelial cell invasion and proliferation: it also requires pericyte coverage of vascular sprouts for vessel stabilization. These processes are coordinated by vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) through their cognate receptors on endothelial cells and vascular smooth muscle cells (VSMCs), respectively. PDGF induces neovascularization by priming VSMCs/pericytes to release pro-angiogenic mediators. Although VEGF directly stimulates endothelial cell proliferation and migration, its role in pericyte biology is less clear. Here we define a role for VEGF as an inhibitor of neovascularization on the basis of its capacity to disrupt VSMC function. Specifically, under conditions of PDGF-mediated angiogenesis, VEGF ablates pericyte coverage of nascent vascular sprouts, leading to vessel destabilization. At the molecular level, VEGF-mediated activation of VEGF-R2 suppresses PDGF-Rbeta signalling in VSMCs through the assembly of a previously undescribed receptor complex consisting of PDGF-Rbeta and VEGF-R2. Inhibition of VEGF-R2 not only prevents assembly of this receptor complex but also restores angiogenesis in tissues exposed to both VEGF and PDGF. Finally, genetic deletion of tumour cell VEGF disrupts PDGF-Rbeta/VEGF-R2 complex formation and increases tumour vessel maturation. These findings underscore the importance of VSMCs/pericytes in neovascularization and reveal a dichotomous role for VEGF and VEGF-R2 signalling as both a promoter of endothelial cell function and a negative regulator of VSMCs and vessel maturation.

Download full-text


Available from: Niren Angle, Aug 19, 2015
  • Source
    • "Studies employing genetic models shed further light onto mechanisms behind vessel normalization. When VEGF 2/2 tumors are grown in wild-type animals, tumor vessels show improved PVC coverage (Greenberg et al. 2008). Similarly, when wild-type tumors are grown in mice with a VEGF 2/2 myeloid cell population, tumors again show greater vessel maturity, reduced hypoxia, and chemosensitivity (Stockmann et al. 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Pathological angiogenesis-driven by an imbalance of pro- and antiangiogenic signaling-is a hallmark of many diseases, both malignant and benign. Unlike in the healthy adult in which angiogenesis is tightly regulated, such diseases are characterized by uncontrolled new vessel formation, resulting in a microvascular network characterized by vessel immaturity, with profound structural and functional abnormalities. The consequence of these abnormalities is further modification of the microenvironment, often serving to fuel disease progression and attenuate response to conventional therapies. In this article, we present the "vascular normalization" hypothesis, which states that antiangiogenic therapy, by restoring the balance between pro- and antiangiogenic signaling, can induce a more structurally and functionally normal vasculature in a variety of diseases. We present the preclinical and clinical evidence supporting this concept and discuss how it has contributed to successful treatment of both solid tumors and several benign conditions.
    Cold Spring Harbor Perspectives in Medicine 03/2012; 2(3):a006486. DOI:10.1101/cshperspect.a006486 · 7.56 Impact Factor
  • Source
    • "The vascular endothelial growth factor family VEGF-A ((often VEGF only), VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placental growth factor (PlGF)) are the most studied angiogenic pathways (Folkman, 1995; Veikkola and Alitalo, 1999). Among these factors, VEGF is the most important angiogenesis stimulating factor and a negative regulator of the function of pericytes and maturation of blood vessels (Carmeliet, 2005; Greenberg et al., 2008).VEGF can maintain survival as well as induce proliferation and migration of endothelial cells, recruit bone marrow derived hematopoietic progenitor or stem cells, and increase vascular permeability (Jain et al., 2006). However, the biologic activities of VEGF must be mediated by two tyrosine kinase receptors, VEGF receptor-1 (VEGFR-1, Flt-1) and VEGFR-2 (KDR) (Ferrara, 2005; Veikkola and Alitalo, 1999). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The present study was based on the unexpected discovery that norcantharidin exerted anti-angiogenesis activity when effects on growth of human colon cancer were studied. The aim was to further verify this finding and explore possible mechanisms using a tumor xenograft model in nude mice. We confirmed that norcantharidin (5 or 15 mg/kg) could inhibit angiogenesis of human colon cancer in vivo. In vitro, crossing river assay, cell adhesion assay and tube formation assay indicated that NCTD could reduce the migration, adhesion and vascular network tube formation ability of HUVECs. At the same time, the expression levels of VEGF and VEGFR-2 proteins which play important roles in angiogenesis were reduced as examined by western blotting analysis. Taken together, the results firstly showed NCTD could inhibit angiogenesis of human colon cancer in vivo, probably associated with effects on migration, adhesion and vascular network tube formation of HUVECs and expression levels of VEGF and VEGFR-2 proteins.
    Asian Pacific journal of cancer prevention: APJCP 02/2012; 13(2):499-503. DOI:10.7314/APJCP.2012.13.2.499 · 2.51 Impact Factor
  • Source
    • "Tumor hypoxia drives VEGF-A expression , and while VEGF-A is a potent mediator of endothelial sprouting and neovascularization, it is not efficient in generating a mature vascular network (Chen et al., 2007). Also, VEGF-A has recently been shown to be a negative regulator of pericyte function and vessel maturation (Greenberg et al., 2008). Thus, hypoxia-triggered proangiogenic factors might impair pericyte recruitment and investment of the tumor vasculature by keeping pericytes in an ''activated'' state (Raza et al., 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Pericytes, the mural cells of blood microvessels, have recently come into focus as regulators of vascular morphogenesis and function during development, cardiovascular homeostasis, and disease. Pericytes are implicated in the development of diabetic retinopathy and tissue fibrosis, and they are potential stromal targets for cancer therapy. Some pericytes are probably mesenchymal stem or progenitor cells, which give rise to adipocytes, cartilage, bone, and muscle. However, there is still confusion about the identity, ontogeny, and progeny of pericytes. Here, we review the history of these investigations, indicate emerging concepts, and point out problems and promise in the field of pericyte biology.
    Developmental Cell 08/2011; 21(2):193-215. DOI:10.1016/j.devcel.2011.07.001 · 10.37 Impact Factor
Show more